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Cystic Fibrosis Lung Microbiome: Opportunities to
Reconsider Management of Airway Infection
Lindsay J. Caverly, MD, Jiangchao Zhao, PhD, and John J. LiPuma, MD
Summary. The importance of infection in the pathogenesis of cystic fibrosis (CF) lung disease
has been long recognized, and the use of antibiotics targeting bacteria identified in cultures of
respiratory specimens has played a critical role in improving outcomes for individuals with CF.
Over the past 15 years, the use of culture-independent methods to assess airway microbiology
in CF has revealed complex and dynamic CF airway bacterial communities. Recent areas of
investigation of the CF lung microbiome have included exploring how bacterial community
structures change over time, particularly with respect to disease progression or pulmonary
exacerbation, and in response to antibiotic therapies. This review will discuss what has
been learned from these studies as well as how these findings offer opportunities to
further refine management of CF airway infection. Pediatr Pulmonol. 2015;50:S31–S38.
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INTRODUCTION
Identification of the important role of infection in the
pathogenesis of cystic fibrosis (CF) lung disease dates
back to the observation of bronchopulmonary infection
with Staphylococcus aureus in autopsies in Andersen’s
initial description of CF in 1938.1 The negative impact
that infection with certain bacterial pathogens has on CF
lung function became well recognized thereafter, and
obtaining bacterial cultures of CF respiratory samples
has been in practice since the 1950s. The results of
respiratory cultures have been used to guide many
aspects of CF care, particularly the choice of antibiotics
to treat pulmonary exacerbations. More recently,
methods to detect the presence of bacteria without
having to recover viable organisms in culture have been
applied to studies of CF microbiology. The use of these
“culture-independent” methods has provided greater
insight into the composition of CF airway bacterial
communities. Improved understanding of these commu-
nities, their relationship to clinical course, and response
to antibiotic therapy offers a promising path toward
continued improvements to our management of CF
airway infection.
CULTURE-INDEPENDENT MOLECULAR
METHODS IDENTIFY GREATER NUMBERS OF
BACTERIAL SPECIES
Initial culture-independent studies of CF airway
microbiology employed a variety of molecular genetic
methods that proved useful in detecting unusual and
otherwise unreported bacteria from CF specimens.2–6
These studies showed that standard bacterial cultures
significantly underrepresent the number of species in CF
airway samples. In an early study, Rogers et al.3 detected
an average of 13 bacterial species per sputum sample from
adults with CF. Since then, studies employing next
generation (or deep) sequencing of the bacterial 16S
ribosomal subunit (16S rRNA) gene have provided even
greater discrimination of bacterial community structure
through detection of species that are difficult to recover in
culture and/or present in low abundances. Culture-
independent methods also allow for the estimation of
bacterial community diversity, defined as a measure of the
number of species present (community richness) and their
relative abundances within the community (community
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evenness). Analyses of bacterial community diversity
have deepened our understanding of CF airway infection
and its association with clinical course.
BACTERIAL COMMUNITY DIVERSITY
DECREASES WITH AGE AND LUNG DISEASE
PROGRESSION
The age specific prevalence of respiratory pathogens
based on bacterial culture of CF specimens is well known.7
Culture-independent analyses have complemented this by
providing greater insight into how respiratory infection
changes over time in CF. The airway bacterial communities
of infants and young childrenwith CF appear to be typically
dominated by Streptococcus and anaerobic genera such as
Veillonella and Prevotella.8 Based on a small number of
longitudinal studies, airway bacterial diversity appears to
increase during the first decade of life.9 Diversity then
decreases throughout adolescence and adulthood in parallel
with lung function decline.9–12 Cross-sectional analyses
have similarly shown a correlation between low community
diversity and poor lung function.9,13–15 Deep sequencing of
bacteria in lung explants taken at the time of transplant
demonstrates the marked constriction of community
diversity in end-stage lung disease.16,17 Conversely, greater
community diversity in adulthood is associated with less
severe and more slowly progressing lung disease.10,18,19
While the association between decreased bacterial commu-
nity diversity and lung disease progression is clear, the
causal relationship between these phenomena has yet to be
fully elucidated.20 Additional longitudinal studies, begin-
ning in infancy, of the patterns of bacterial community
structure, together with careful analysis of the factors that
may influence this structure, will provide opportunities to
refine current antibioticmanagement strategies to prevent or
slow lung function decline.
CHANGES IN BACTERIAL COMMUNITY
STRUCTURE ASSOCIATED WITH PULMONARY
EXACERBATION
Despite the importance of pulmonary exacerbation in
CF, many questions remain unanswered regarding the
pathophysiology of these events.21–24 Consequently,
understanding the changes in airway microbial commu-
nity structure and activity that occur around the time of
exacerbation onset is an area of great interest. Contrary to
conventional wisdom, culture-independent analyses indi-
cate that total airway bacterial density typically does not
increase with the onset of pulmonary exacerba-
tion.10,14,25,26 Further, predictable changes in overall
bacterial community composition at the onset of
exacerbation have not been found.10,13,14,27 Nevertheless,
changes in community composition with exacerbation
onset have been observed in some individuals.14,26 In one
study, communities dominated by Pseudomonas
experienced a decrease in both the relative and absolute
abundances of Pseudomonas with exacerbation.14 This
intriguing finding suggests a potential role for less
abundant species in contributing to pulmonary exacer-
bations. Whether or not individuals would benefit from
antibiotic therapy directed at these species during an
exacerbation remains to be determined. Deep sequencing
studies also have identified airway bacterial communities
that do not include typical CF pathogens. The use of
culture-independent methods has the potential to shed
light on the pathophysiology of such “culture-negative”
exacerbations.28 These findings suggest the potential for
identifying changes in the airway microbiota that herald
exacerbation onset. Such biomarkers could, in turn,
provide new opportunities for more timely and appropri-
ate treatment of pulmonary exacerbation.
RESILIENT BACTERIAL COMMUNITIES
EVENTUALLY BECOME RESISTANT TO CHANGE
Greater understanding of CF lung microbiota has the
potential for influencing the choice of antibiotic agent,
route, and treatment duration for pulmonary exacerba-
tions. The degree to which airway bacterial communities
change with perturbation—such as that caused by acute
antibiotic treatment in the setting of exacerbation—is
dependent on their level of diversity. Bacterial communi-
ties with relatively high diversity (e.g., those found in
younger children and in milder lung disease) can exhibit
significant change in community structure with antibiotic
therapy.10,14 These changes tend to be temporary,
however, and communities quickly return to their baseline
structures.12,13,29–31 In ecological terms, such communi-
ties are described as being resilient. In contrast, and as
might be expected, the structures of communities with
relatively low diversity (e.g., dominated by a single
species, as is often observed in late stage disease)
experience little apparent change with antibiotic treat-
ment.13,14,32 They lack the dynamic range of more diverse
communities and are described in ecological terms as
being resistant to perturbation.
Although the drivers of decreasing diversity and
increasing community resistance that occur over time
are not well understood, it appears that repeated antibiotic
administration plays an important role. In children,
community diversity is inversely correlated with antibi-
otic exposure.39 In a longitudinal study of adults with CF,
antibiotic use was found to be the primary predictor of
decreased diversity,10 and long-term antibiotic use in
adults has been associated with decreased richness of
bacterial communities.33 The route, specific type, and
number of antibiotics administered are likely important
variables in shaping community structure in the long
term.34 Again, further study is needed to better define
the role repeated antibiotic use has in determining the
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fate of airway communities in both the short and
long terms, and how therapies can be optimized
accordingly.
ANAEROBES ARE FREQUENTLY DETECTED IN
AIRWAY COMMUNITIES
Although the identification of anaerobic bacteria and
their consideration as potential pathogens in CF dates
back to the early 1980s,35,36 the prevalence of these
species in CF airways and the role they may have in
contributing to lung disease has remained poorly defined.
Among the impediments to a better understanding of
these questions is that anaerobic bacterial culture requires
techniques and conditions that are not routinely included
in standard culturing protocols for CF airway samples.
Culture-independent investigations of the CF airway
microbiota, however, have illuminated the presence and
diversity of anaerobic species in the CF air-
ways.2,3,5,13,19,37–39 Anaerobes are highly prevalent in
CF respiratory samples irrespective of patient age and
sampling method, including oropharyngeal (OP) swabs,
expectorated sputum, bronchoalveolar lavage (BAL), and
lower airway plugs obtained from lung explants.37,40,41
Importantly, anaerobic species are frequently detected in
abundances equal to or greater than those observed for
typical pathogens such as P. aeruginosa.13,40 Among the
most prevalent anaerobic species in CF airways are
Prevotella and Veillonella,30,37 although a wide range of
species has been described.
The detection of obligate and facultative anaerobic
species, which are inhabitants of the healthy upper airway,
has been attributed to “contamination” of respiratory
specimens by oral microbiota. However, a number of
studies provide evidence supporting the presence of
anaerobes in the lower airways. Harris et al.5 analyzed
BAL samples from 28 children with CF. These samples
would be expected to be only minimally contaminated by
bacteria in the oropharynx, which is largely bypassed in
BAL sampling. Nevertheless, rich bacterial communities
were identified, composed of, among other species,
obligate and facultative anaerobic species, including high
relative abundance of Streptococcus, Prevotella, and
Fusobacterium. In a recent study, Brown et al.42
performed deep sequencing on sections of lung resected
from a young child with severe CF lung disease. A diverse
microbiota was detected in the lung tissue, including
several anaerobic species that are inhabitants of the
healthy oral cavity. Because the lung tissuewas surgically
removed, sectioned and processed under sterile con-
ditions, the anaerobic species detected therein could not
have resulted from oropharyngeal contamination during
sampling.
Recent metagenomic and metatranscriptomic analyses
of CF respiratory samples provide compelling evidence of
microbial anaerobic respiration in the CF lung, suggesting
that anaerobes not only reside in the airways but play a
role in CF lung disease.43 Although CF patients with or
without anaerobes identified by deep sequencing did not
differ in overall lung function in cross sectional
studies,37,40 Zemanick et al.44 found that among children
with CF, the relative abundance of Prevotella was
positively associated with lung function and negatively
associated with markers of airway inflammation. This
suggests that the presence of certain anaerobes may be a
marker of “healthier,” more diverse bacterial communi-
ties, such as are found in children with mild lung disease
that have not yet been treated with intensive antibiotic
therapy. In contrast, facultative anaerobic species,
including Gemella,14 Rothia,45 and members of the
“Streptococcus milleri” group46 have been associated
with pulmonary exacerbations in adults with CF, and
recently, DNA sequencing based microbial profiling has
shown that fermentative anaerobes become more abun-
dant during exacerbation.47 Observations such as these
have prompted renewed interest in reconsidering of the
use of antibiotics with greater activity against anaerobic
species in CF.
HOW REPRESENTATIVE IS SPUTUM OF THE
LOWER AIRWAYS MICROBIOTA?
In order for studies of the CF lung microbiome to
continue to advance our knowledge of CF microbiology
and lead to further improvements in the management of
airway infection, several technical aspects of conducting
these studies are worth considering. The first involves the
type of sampling method used to represent the airway
microbiome. The use of expectorated sputum to assess the
airwaymicrobiota in CF (as well as in COPD and asthma)
has been criticized as being poorly representative of
microbiota present in the lower airways. The detection of
bacterial species that are typical inhabitants of the healthy
human oropharynx, particularly anaerobes, has exacer-
bated these concerns, although several studies provide
strong evidence that anaerobes do indeed reside in the CF
lower airways.5,42 Further, the categorization of micro-
biota into oropharyngeal and airway compartments is
somewhat artificial in that these compartments are
contiguous, with the contents of one being reflected in
the composition of the other. Venkataraman et al.48
employed an ecological “neutral biodiversity model” to
conclude that dispersal of microbes from the oral cavity is
the primary driver of the composition of the healthy lung
microbiome. Bassis et al.49 used deep sequencing to
compare microbiota in sets of mouthwash, BAL fluid,
nasal swab, and gastric aspirate samples from 28 healthy
subjects. Their analysis similarly showed that microbial
migration from the oral cavity was a significant source of
the lung microbiota during health. Similarly, Hansen
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et al.50 have presented data showing that the sinuses in
people with CF provide bacterial pathogens with a niche
for adaptation to the host and a reservoir for seeding of the
lower respiratory tract. Finally, Whiteson et al.51 applied
an island biogeography ecological model to conclude that
the detection of oral microbes in CF sputum or BAL
samples more likely represents immigration from the
oropharynx to the airways, rather than mere contamina-
tion of respiratory samples.
As expectoration of sputum necessitates its passage
through the non-sterile oropharynx, it is expected that oral
bacteria will be detected in sputum samples. However,
several lines of evidence indicate that oral bacteria have
only amarginal impact onmeasures of airwaymicrobiota.
Direct comparisons of oral and lower airways samples
have found differences in the microbiota between these
sites. Rogers et al.52 compared bacterial community
structures in sets of expectorated sputum and mouthwash
samples obtained from 19 adult CF patients. Overall, the
great majority of species detected in mouthwash were not
detected in any sputum samples. Conversely, nearly one-
third of the species detected in the sputum samples were
not detected in any of the mouthwash samples. In the
majority of patients, species detected in both sputum
and mouthwash differed in their relative abundances
between the two sample types. Similarly, Zemanick
et al.53 compared induced and expectorated sputum
with OP and saliva samples, and found distinct lower
and upper airway communities in many individuals. In
a study by Filkins et al.,54 deep sequencing showed
significant differences between CF inpatients and out-
patients with respect to the abundance of Streptococcus, a
frequent member of oral bacterial communities. Since
both patient groups provided expectorated sputum,
potential contamination of samples with oro-pharyngeal
microbiota would have affected both groups equally,
suggesting that the differences seen reflected true differ-
ences in the abundance of Streptococcus in the lower
airways.
Finally, sputum samples are frequently dominated by
species not typically considered major components of
“oral flora,” arguing against significant oral contamina-
tion. In a longitudinal study, Zhao and colleagues10
observed dramatic changes in bacterial community
structure in serial sputum samples obtained from adult
CF patients over the course of 8–9 years. Reproducible
community profiles, allowing differentiation of individual
patients, were found. Communities were most often
dominated by species that are known lower airway
pathogens in CF, including Pseudomonas aeruginosa,
Staphylococcus aureus, and Achromobacter sp. In
patients with advanced lung disease, communities in
sputum were highly constrained, often being heavily
dominated by a single non-oral species, as has been
observed in CF lung explant specimens.17
IS USING OP SWAB SAMPLES IN NON-
EXPECTORATING INDIVIDUALS WORTHWHILE?
OP swabs have also been criticized as being poorly
representative of microbiota present in the lower airways.
In an analysis of the microbiota in resected lung from a
child with CF, Brown et al.42 observed that none of the
most abundant species detected by deep sequencing were
recovered in routine culture of the child’s OP swab sample
or by sequence analysis of the swab sample, suggesting
that OP swabs may poorly reflect species in diseased
lower airways.42 Goddard et al.17 similarly identified
discordance between themicrobiota identified from throat
swabs and lung explants. Recently, Zemanick et al.53
assessed the airway microbiota in concurrently collected
saliva, OP swab, induced sputum, and expectorated
sputum samples from 16 children with CF. Higher relative
abundances of Pseudomonas and Staphylococcus were
detected in induced and expectorated sputum than in
the respective OP and saliva samples. Increased diver-
gence between microbiota in induced or expectorated
sputum compared to microbiota in saliva or OP swab
samples was associated with increased markers of airway
inflammation, suggesting that as lung disease (and
inflammation) worsens, OP swab samples more poorly
reflect lower airwaymicrobiota. Nevertheless, differences
in bacterial communities were greater between patients
than were differences between sampling methods within
individual patients, indicating that in the absence of
expectorated sputum, OP swab samples may provide a
tractable model by which to assess airway microbial
community dynamics within individuals.
CAN LIVE VERSUS DEAD BACTERIA BE
DIFFERENTIATED AND DOES IT MATTER?
Another technical consideration in designing and
interpreting studies of the CF lung microbiome involves
the viability of the bacteria identified. Analyses of
CF airway microbiota using deep sequencing most
often have not differentiated viable and nonviable
bacteria.5,10,14,27,34,43–47,51,53–61 That is, typically, DNA
from both dead and alive organisms is extracted from a
respiratory specimen and sequenced to provide a profile
of the bacterial community in the airway. This has raised
concern that culture-independent approaches do not
accurately reflect metabolically active bacterial commu-
nities residing in the airways. The use of propidium
monoazide (PMA) to block sequencing of DNA that is not
associated with living bacterial cells has been pro-
posed.62–66 PMA is able to penetrate only damaged or
dead bacterial cells, where it binds to DNA upon
photoactivation, preventing the DNA from being ampli-
fied and sequenced. However, the accuracy of PMA in
differentiating viable from nonviable bacterial cells is
dependent on cell type, and on several experimental
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conditions, including PMA concentration, light exposure
time, specimen quality, and incubation time and
temperature.67 The use of PMA also tends to overestimate
the number of viable bacteria by detecting nonviable but
membrane intact cells.68,69 Of particular note for studies
of CF airway microbiota is that freezing and thawing of
respiratory specimens is likely to lyse viable bacteria
therein.62 Thus, unless samples are processed immediate-
ly, PMA treatment would be expected to underestimate
the viable bacteria found in the sample prior to freeze-
thaw.
The limitations of PMA (or other methods) in
differentiating viable from nonviable bacteria notwith-
standing, the degree to which the detection of
extracellular bacterial DNA confounds interpretation
of analyses of CF airway microbiome is not clear.
Airway bacterial communities show marked changes in
their structures shortly after the initiation of antibiotic
therapy, an observation that would not be expected if
DNA from nonviable bacterial cells was present in
appreciable quantities.10,12,30 One may also argue that
extracellular DNA, which is not biologically inert and
may be important in estimating the “burden” of some
species (e.g., extracellular DNA in P. aeruginosa
biofilm), should not be eliminated from microbiome
analyses. Ultimately, the decision to attempt to limit
measuring extracellular DNA hinges on the specific
question being addressed.
CONCLUSIONS
The use of culture-independent molecular methods has
expanded our understanding of CF airway microbiology
and has highlighted several areas of opportunity to
reconsider management of airway infection in CF
(Table 1). Although the bacterial species included in
the small suite of opportunists associated with CF
lung disease remain the dominant pathogens, we now
recognize that the CF airways often harbor complex
microbial communities, and that anaerobic species are
frequently detected in relatively high abundances in these
communities. Change in the structure of these communi-
ties correlates with lung disease progression in the long
term and, most likely, with clinical status (e.g.,
exacerbation) in the short term. Ongoing and future
research on the CF lung microbiome offers a promising
path to translate these findings into improvements in
clinical care. Are there treatment approaches that would,
for example, better maintain airway microbial communi-
ties that seem to be associated with relatively more
favorable clinical outcomes? Should consideration be
given to the greater use of antimicrobials targeting
anaerobic species, particularly in treating pulmonary
exacerbations? Will species heretofore not associated
with lung disease progression—or combinations of
species that correlate with worsening clinical state—be
identified?
Further culture-independent study of the CF airway
microbiome has considerable potential to address
questions such as these. The practical application
of this approach in the care of CF patients, however,
cannot rely on repeated invasive sampling of the
lower airway. The translational utility of microbiome
analysis, ultimately, will rely on assessing respiratory
specimens obtained non-invasively to identify reliable,
reproducible measures that track with clinical features
of disease progression and can be used to inform future
therapies. Debates over whether or not culture-indepen-
dent analysis of expectorated sputum or OP swabs
provides a precise representation of the lower airway
community, or whether or not deep sequencing should
be performed on DNA from “viable” bacteria only, are
less relevant in this context. The knowledge gained
regarding the CF lung microbiome over the past 15
years described here has laid the groundwork for
ongoing and future work in this field, with the ultimate
goal of continuing to improve outcomes for individuals
with CF.
TABLE 1—Future Research Questions
Long-term airway bacterial community dynamics:
What is the causal relationship between decreasing community diversity and advancing age and lung disease?
What are the drivers of the decreasing community diversity associated with advancing age and lung disease?
Would maintaining more diverse communities have a positive impact on lung health? If so, are there treatment options that may enable
maintenance of ‘healthier’ airway communities?
Short-term airway bacterial community dynamics:
Are there reliable changes in community structure and/or activity that are associated with changes in clinical state?
Can biomarkers of impending exacerbation be identified? If so, can these be monitored in real time and exploited to prevent exacerbation?
Are there community changes that predict exacerbation severity and/or recovery from exacerbation? If so, can these be employed to refine
therapy of exacerbation?
Role of anaerobes in CF health and disease:
What is the role of obligate and facultative anaerobic species in contributing to lung disease progression?
Would antimicrobial therapy targeting anaerobic species provide better treatment of exacerbation (in the short term) or further decrease
community diversity (in the long term)?
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